Ubs Group Ag In8 Bio, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in In8 Bio, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 12,327 shares of INAB stock, worth $1,849. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,327

Previous 58,853 79.05%

Holding current value

$1,849

Previous $15,000 86.67%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$0.17 - $0.35 $7,909 - $16,284	-46,526 Reduced 79.05%	12,327 $2,000
Q4 2024 Feb 14, 2025	BUY	$0.23 - $0.48 $7,494 - $15,639	32,583 Added 124.03%	58,853 $15,000
Q3 2024 Nov 14, 2024	BUY	$0.27 - $0.88 $7,092 - $23,117	26,270 New	26,270 $7,000
Q4 2023 Feb 09, 2024	SELL	$0.69 - $2.34 $319 - $1,083	-463 Reduced 9.32%	4,505 $6,000
Q3 2023 Nov 09, 2023	BUY	$0.92 - $1.74 $4,570 - $8,644	4,968 New	4,968 $5,000
Q1 2023 May 12, 2023	SELL	$1.17 - $2.83 $382 - $925	-327 Reduced 9.45%	3,133 $4,000
Q4 2022 Feb 08, 2023	SELL	$1.39 - $2.47 $7,316 - $13,002	-5,264 Reduced 60.34%	3,460 $7,000
Q3 2022 Nov 10, 2022	BUY	$1.77 - $2.89 $8,326 - $13,594	4,704 Added 117.01%	8,724 $18,000
Q2 2022 Aug 10, 2022	BUY	$2.02 - $4.68 $361 - $837	179 Added 4.66%	4,020 $9,000
Q1 2022 May 16, 2022	BUY	$2.76 - $4.6 $5,815 - $9,692	2,107 Added 121.51%	3,841 $13,000
Q4 2021 Feb 14, 2022	SELL	$4.39 - $8.55 $7,467 - $14,543	-1,701 Reduced 49.52%	1,734 $8,000
Q3 2021 Nov 15, 2021	BUY	$6.71 - $10.0 $23,048 - $34,350	3,435 New	3,435 $24,000

Others Institutions Holding INAB

# of Institutions

Shares Held

21.7M

Call Options Held

Put Options Held

View Full List

About IN8BIO, INC.

Ticker INAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,502,200
Market Cap $3.68M
Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...

More about INAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account